Lyell Immunopharma, Inc. (LYEL)

NMS – Real Time Price. Currency in USD

19.25

+0.05 (0.26%)

At close: May 12, 2026, 4:00 PM EDT

19.25

0.00 (0.00%)

After-hours: May 12, 2026, 4:10 PM EDT

06.05.2026

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

PiNACLE pivotal clinical trial evaluating ronde-cel in patients with LBCL in third- or later-line setting on track to report additional data in second half of 2026, with pivotal data expected mid-2027 and BLA submission expected to follow in 2027 PiNACLE-H2H, a first of its kind Phase 3 clinical trial evaluating ronde-cel head-to-head against standard-of-care CD19 CAR T-cell therapies in the LBCL second-line setting, commenced patient dosing Phase 1 clinical trial of LYL273 continues to enroll patients with metastatic colorectal cancer, with commencement of patient dosing at Dose Level 3 Closed second $50 million tranche of $100 million private placement at $25.61 per share, with approximately $261 million in cash as of March 31, 2026, expected to provide runway into Q3 2027 SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today reported financial results and business highlights for the first quarter ended March 31, 2026.

17.04.2026

Lyell Immunopharma, Inc. (LYEL) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

07.04.2026

Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will present and participate in the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026, at 11:00 am Eastern Time.

23.03.2026

Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet

Lyell Immunopharma is a CAR-T developer with a single pivotal asset, ronde-cel, targeting LBCL and showing superior early efficacy and safety data. Ronde-cel's 93% ORR, 76% CR, and ~18-month mPFS in 3L+ LBCL patients outperformed approved peers, supporting a $1B+ peak sales opportunity. Valuation estimates suggest LYEL equity value of ~$45–55 per share, with the current price reflecting moderate success probability; pivotal data in 2027 is key.

12.03.2026

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

SOUTH SAN FRANCISCO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2025. Lyell has since commenced patient dosing in the first-of-its-kind Phase 3 head-to-head CAR T-cell randomized controlled clinical trial of rondecabtagene autoleucel (ronde-cel) versus investigator's choice of axicabtagene ciloleucel (axi-cel) or lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) with disease progression on at least one prior line of therapy (PiNACLE-H2H). Lyell has dosed seven new patients with metastatic colorectal cancer (mCRC) with LYL273, an enhanced guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate, since its November 2025 acquisition, without dose-limiting toxicity and including dose escalation to Dose Level 3.

09.03.2026

Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer

SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced it has closed the sale of an additional $50 million of shares of its common stock to investors from its July 2025 equity private placement of up to $100 million, following achievement of a clinical milestone within its PiNACLE pivotal trial evaluating rondecabtagene autoleucel (ronde-cel) in patients with relapsed/refractory large B-cell lymphoma (LBCL) in the third- or later-line setting. The Company also announced the appointment of Smital Shah as its Chief Financial and Business Officer, effective March 9, 2026.

06.03.2026

Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Videos

No Data

There is no data to display

Press releases

06.05.2026

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

07.04.2026

Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference

12.03.2026

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

09.03.2026

Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer

Lyell Immunopharma, Inc. (LYEL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Lyell Immunopharma, Inc. (LYEL)

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

Lyell Immunopharma, Inc. (LYEL) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference

Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer

Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Videos

No Data

Press releases

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

Lyell Immunopharma, Inc. (LYEL) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference

Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer

Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Videos

No Data

Press releases

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer

Search stocks

Lyell Immunopharma, Inc. (LYEL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Lyell Immunopharma, Inc. (LYEL)

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

Lyell Immunopharma, Inc. (LYEL) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference

Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer

Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Videos

No Data

Press releases

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

Lyell Immunopharma, Inc. (LYEL) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference

Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer

Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Videos

No Data

Press releases

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer